SCHEMBL6778331

SCHEMBL6778331

C[C@@H](O)CNC(=O)N1CC(c2ccc(C(F)(F)F)cc2)C1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TACR1 P25103 3/20 0.45
SLC6A9 P48067 2/20 0.43
KCNH2 Q12809 2/20 0.43
CHRM2 P08172 1/20 0.42
CHRM5 P08912 1/20 0.42
CHRM1 P11229 1/20 0.42
CHRM3 P20309 1/20 0.42
ACACB O00763 2/20 0.42
TRPM8 Q7Z2W7 1/20 0.42
PROKR1 Q8TCW9 1/20 0.41
PAX8 Q06710 1/20 0.40
F2R P25116 1/20 0.40
RORC P51449 1/20 0.40
NAMPT P43490 3/20 0.40
CCR2 P41597 1/20 0.40
LIPE Q05469 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6778334 1.00 TACR1 (0.45) TACR1SLC6A9KCNH2CHRM2CHRM5
SCHEMBL6783908 1.00 TACR1 (0.45) TACR1SLC6A9KCNH2CHRM2CHRM5
SCHEMBL6774355 0.89 ACACB (0.47) TACR1ACACBNAMPTLIPE
SCHEMBL6774352 0.89 ACACB (0.47) TACR1ACACBNAMPTLIPE
SCHEMBL6896250 0.86 GRIN2B (0.47) CHRM2CCR2
SCHEMBL6896252 0.86 GRIN2B (0.47) CHRM2CCR2
SCHEMBL7552865 0.86 GRIN2B (0.47) CHRM2CCR2
SCHEMBL6774775 0.86 PRMT5 (0.48) TACR1NAMPTCCR2
SCHEMBL6774773 0.86 PRMT5 (0.48) TACR1NAMPTCCR2
SCHEMBL6777723 0.86 PRMT5 (0.48) TACR1NAMPTCCR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831078-B1 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant VERNALIS RESEARCH LIMITED (GB) 2004-12-14 US claimed
EP-1049670-B1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RES LTD (GB) 2002-07-17 EP claimed
EP-1049670-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 2000-11-08 EP claimed
WO-1999037613-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 1999-07-29 WO claimed
US-6831078-B1 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant VERNALIS RESEARCH LIMITED (GB) 2004-12-14 US disclosed
EP-1049670-B1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RES LTD (GB) 2002-07-17 EP disclosed
EP-1196165-A2 AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES VERNALIS RESEARCH LIMITED (GB) 2002-04-17 EP disclosed
WO-2001007022-A2 AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES VERNALIS RESEARCH LIMITED (GB) 2001-02-01 WO disclosed
EP-1049670-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 2000-11-08 EP disclosed
WO-1999037613-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 1999-07-29 WO disclosed